Published online Aug 28, 2021. doi: 10.3748/wjg.v27.i32.5448
Peer-review started: March 26, 2021
First decision: April 29, 2021
Revised: April 30, 2021
Accepted: July 23, 2021
Article in press: July 23, 2021
Published online: August 28, 2021
Processing time: 151 Days and 19.4 Hours
Clinical manifestations of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus are heterogenous and can affect different organs, including the gastrointestinal tract. Angiotensin converting enzyme 2 receptor, which mediates SARS-CoV-2 infection, is abundantly present in the intestinal mucosa.
Since the cytokine storm mediated by SARS-CoV-2 in coronavirus disease 19 (COVID-19) seems to determine a vascular damage which could explain hypercoagulability and pulmonary embolism, intestinal ischemic events in SARS-CoV-2 positive patients may be linked to the same pathogenic mechanism.
The aim of the present study is to collect and analyse the intestinal ischemic events in SARS-CoV-2 positive patients in order to calculate the incidence and determine the prognosis of affected subjects.
The study was designed as a retrospective observational multicentre collection involving three among the largest COVID hospitals in Lombardy.
Intestinal ischemia is a rare but fatal manifestation of SARS-CoV-2 infection. The condition should be suspected in case of severe abdominal pain. In order to define localization and extent of intestinal ischemia, abdominal computed tomography scan and possibly endoscopy should be carried out. Intestinal biopsies main finding is endotheliitis.
Severe endotheliitis in the intestinal mucosa could mediate intestinal ischemic manifestations in the gastrointestinal tract. Such manifestations are rare but frequently fatal, thus they should be ruled out in SARS-CoV-2 positive patients with gastroin
One of the possible mechanisms of ischemic intestinal manifestations of SARS-CoV-2 could be mediated by mannan-binding lectin-associated serine protease-2 which is also a possible target for future therapy of COVID-19.
